Trial Profile
Phase I dose escalation of Gleevec [imatinib] in combination with PTK787/ZK 222584 (PTK/ZK) [vatalanib] plus hydroxyurea.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2013
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Vatalanib (Primary) ; Hydroxycarbamide
- Indications Glioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jan 2008 Status changed from recruiting to in progress.